Gapping up
In reaction to earnings/guidance:
- DNUT +2.2% (raises guidance)
Other news:
- VRS +32.1% (to be acquired for $27.00 per share)
- ITCI +19.2% (receives FDA approval for CAPLYTA)
- ARGX +8.8% (confirms FDA approval of VYVGART)
- CIT +8.2% (Fed announces unanimous approval allowing First Citizens BancShares to acquire CIT Group)
- MRNA +7.6% (reports preliminary booster data and updates strategy to address Omicron Variant)
- VXX +6.9% (trading higher with futures under pressure)
- BGNE +5.6% (signs strategic collaboration with Novartis (NVS) to advance clinical development of ociperlimab in combination with tislelizumab)
- FCNCA +4.6% (Fed announces unanimous approval allowing First Citizens BancShares to acquire CIT Group)
- CTSO +4.4% (Publication of U.S. CTC Multicenter Registry Results Using CytoSorb in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation)
- CARA +1.6% (KORSUVA receives TDAPA reimbursement beginning April 2022)
Analyst comments:
- LLNW +6.8% (upgraded to Strong Buy from Mkt Perform at Raymond James)
- CERN +1.6% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
- RLGY +1.2% (upgraded to Overweight from Neutral at JP Morgan)